Stockreport

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

IN8bio, Inc.  (INAB) 
PDF Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated [Read more]